HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.
An important hallmark of CRC is the evasion of immune surveillance. HLA-G is a negative regulator of host's immune response. Overexpression of HLA-G protein in primary tumour CRC tissues has already been associated to worse prognosis; however a definition of the role of immunogenetic host backg...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4669157?pdf=render |
id |
doaj-6727e3b8b32c4fa2b74573e56787b119 |
---|---|
record_format |
Article |
spelling |
doaj-6727e3b8b32c4fa2b74573e56787b1192020-11-24T21:36:43ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-011012e014400010.1371/journal.pone.0144000HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.Marica GarzieraEttore BidoliErika CecchinEnrico MiniStefania NobiliSara LonardiAngela BuonadonnaDomenico ErranteNicoletta PellaMario D'AndreaFrancesco De MarchiAntonino De PaoliChiara ZanussoElena De MattiaRenato TassiGiuseppe ToffoliAn important hallmark of CRC is the evasion of immune surveillance. HLA-G is a negative regulator of host's immune response. Overexpression of HLA-G protein in primary tumour CRC tissues has already been associated to worse prognosis; however a definition of the role of immunogenetic host background is still lacking. Germline polymorphisms in the 3'UTR region of HLA-G influence the magnitude of the protein by modulating HLA-G mRNA stability. Soluble HLA-G has been associated to 3'UTR +2960 Ins/Ins and +3035 C/T (lower levels) and +3187 G/G (high levels) genotypes. HLA-G 3'UTR SNPs have never been explored in CRC outcome. The purpose of this study was to investigate if common HLA-G 3'UTR polymorphisms have an impact on DFS and OS of 253 stage II-III CRC patients, after primary surgery and ADJ-CT based on FL. The 3'UTR was sequenced and SNPs were analyzed for their association with survival by Kaplan-Meier and multivariate Cox models; results underwent internal validation using a resampling method (bootstrap analysis). In a multivariate analysis, we estimated an association with improved DFS in Ins allele (Ins/Del +Ins/Ins) carriers (HR 0.60, 95% CI 0.38-0.93, P = 0.023) and in patients with +3035 C/T genotype (HR 0.51, 95% CI 0.26-0.99, P = 0.045). The +3187 G/G mutated carriers (G/G vs A/A+A/G) were associated to a worst prognosis in both DFS (HR 2.46, 95% CI 1.19-5.05, P = 0.015) and OS (HR 2.71, 95% CI 1.16-6.63, P = 0.022). Our study shows a prognostic and independent role of 3 HLA-G 3'UTR SNPs, +2960 14-bp INDEL, +3035 C>T, and +3187 A>G.http://europepmc.org/articles/PMC4669157?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Marica Garziera Ettore Bidoli Erika Cecchin Enrico Mini Stefania Nobili Sara Lonardi Angela Buonadonna Domenico Errante Nicoletta Pella Mario D'Andrea Francesco De Marchi Antonino De Paoli Chiara Zanusso Elena De Mattia Renato Tassi Giuseppe Toffoli |
spellingShingle |
Marica Garziera Ettore Bidoli Erika Cecchin Enrico Mini Stefania Nobili Sara Lonardi Angela Buonadonna Domenico Errante Nicoletta Pella Mario D'Andrea Francesco De Marchi Antonino De Paoli Chiara Zanusso Elena De Mattia Renato Tassi Giuseppe Toffoli HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment. PLoS ONE |
author_facet |
Marica Garziera Ettore Bidoli Erika Cecchin Enrico Mini Stefania Nobili Sara Lonardi Angela Buonadonna Domenico Errante Nicoletta Pella Mario D'Andrea Francesco De Marchi Antonino De Paoli Chiara Zanusso Elena De Mattia Renato Tassi Giuseppe Toffoli |
author_sort |
Marica Garziera |
title |
HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment. |
title_short |
HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment. |
title_full |
HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment. |
title_fullStr |
HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment. |
title_full_unstemmed |
HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment. |
title_sort |
hla-g 3'utr polymorphisms impact the prognosis of stage ii-iii crc patients in fluoropyrimidine-based treatment. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2015-01-01 |
description |
An important hallmark of CRC is the evasion of immune surveillance. HLA-G is a negative regulator of host's immune response. Overexpression of HLA-G protein in primary tumour CRC tissues has already been associated to worse prognosis; however a definition of the role of immunogenetic host background is still lacking. Germline polymorphisms in the 3'UTR region of HLA-G influence the magnitude of the protein by modulating HLA-G mRNA stability. Soluble HLA-G has been associated to 3'UTR +2960 Ins/Ins and +3035 C/T (lower levels) and +3187 G/G (high levels) genotypes. HLA-G 3'UTR SNPs have never been explored in CRC outcome. The purpose of this study was to investigate if common HLA-G 3'UTR polymorphisms have an impact on DFS and OS of 253 stage II-III CRC patients, after primary surgery and ADJ-CT based on FL. The 3'UTR was sequenced and SNPs were analyzed for their association with survival by Kaplan-Meier and multivariate Cox models; results underwent internal validation using a resampling method (bootstrap analysis). In a multivariate analysis, we estimated an association with improved DFS in Ins allele (Ins/Del +Ins/Ins) carriers (HR 0.60, 95% CI 0.38-0.93, P = 0.023) and in patients with +3035 C/T genotype (HR 0.51, 95% CI 0.26-0.99, P = 0.045). The +3187 G/G mutated carriers (G/G vs A/A+A/G) were associated to a worst prognosis in both DFS (HR 2.46, 95% CI 1.19-5.05, P = 0.015) and OS (HR 2.71, 95% CI 1.16-6.63, P = 0.022). Our study shows a prognostic and independent role of 3 HLA-G 3'UTR SNPs, +2960 14-bp INDEL, +3035 C>T, and +3187 A>G. |
url |
http://europepmc.org/articles/PMC4669157?pdf=render |
work_keys_str_mv |
AT maricagarziera hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment AT ettorebidoli hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment AT erikacecchin hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment AT enricomini hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment AT stefanianobili hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment AT saralonardi hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment AT angelabuonadonna hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment AT domenicoerrante hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment AT nicolettapella hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment AT mariodandrea hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment AT francescodemarchi hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment AT antoninodepaoli hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment AT chiarazanusso hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment AT elenademattia hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment AT renatotassi hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment AT giuseppetoffoli hlag3utrpolymorphismsimpacttheprognosisofstageiiiiicrcpatientsinfluoropyrimidinebasedtreatment |
_version_ |
1725939833730236416 |